FLT1 Protein (VEGF Receptor 1)
Overview
FLT1, also known as vascular endothelial growth factor receptor 1 (VEGFR-1) or fms-like tyrosine kinase 1, is a transmembrane receptor tyrosine kinase encoded by the FLT1 gene located on chromosome 13q12. This receptor is a key regulator of vascular biology and immune function, with emerging evidence supporting its involvement in neuroprotection and neuroinflammatory processes relevant to neurodegenerative diseases. FLT1 was first identified in 1990 and has since been recognized as a critical mediator of angiogenesis, inflammation, and neuronal survival in both physiological and pathological conditions of the central nervous system.
Function/Biology
FLT1 is a receptor for vascular endothelial growth factor-A (VEGF-A), placental growth factor (PlGF), and VEGF-B. The protein exists as a full-length transmembrane form (tflt1) and a soluble circulating form (sflt1), which is generated through alternative splicing and post-translational cleavage. The extracellular domain contains seven immunoglobulin-like domains that facilitate ligand binding, while the intracellular domain harbors tyrosine kinase activity required for signal transduction.
...FLT1 Protein (VEGF Receptor 1)
Overview
FLT1, also known as vascular endothelial growth factor receptor 1 (VEGFR-1) or fms-like tyrosine kinase 1, is a transmembrane receptor tyrosine kinase encoded by the FLT1 gene located on chromosome 13q12. This receptor is a key regulator of vascular biology and immune function, with emerging evidence supporting its involvement in neuroprotection and neuroinflammatory processes relevant to neurodegenerative diseases. FLT1 was first identified in 1990 and has since been recognized as a critical mediator of angiogenesis, inflammation, and neuronal survival in both physiological and pathological conditions of the central nervous system.
Function/Biology
FLT1 is a receptor for vascular endothelial growth factor-A (VEGF-A), placental growth factor (PlGF), and VEGF-B. The protein exists as a full-length transmembrane form (tflt1) and a soluble circulating form (sflt1), which is generated through alternative splicing and post-translational cleavage. The extracellular domain contains seven immunoglobulin-like domains that facilitate ligand binding, while the intracellular domain harbors tyrosine kinase activity required for signal transduction.
Upon ligand binding, FLT1 undergoes homodimerization or heterodimerization with other VEGF receptors (primarily VEGFR-2/KDR), triggering autophosphorylation of tyrosine residues in the activation loop. This phosphorylation recruits and activates downstream signaling adaptor proteins, including phospholipase C-gamma (PLCγ), Src family kinases, and protein kinase C (PKC). These cascades activate multiple intracellular pathways including the phosphatidylinositol 3-kinase/Akt (PI3K/Akt) pathway, mitogen-activated protein kinase (MAPK) cascade, and calcium signaling, ultimately regulating endothelial cell migration, permeability, and survival.
Notably, FLT1 exhibits approximately 10-fold higher ligand-binding affinity than VEGFR-2 for certain ligands, particularly PlGF, positioning it as a critical modulator of ligand availability and receptor signaling balance. Soluble FLT1 acts as a physiological antagonist by sequestering circulating VEGF ligands, thereby regulating free VEGF bioavailability and fine-tuning angiogenic responses.
Role in Neurodegeneration
FLT1 participates in multiple pathogenic mechanisms implicated in neurodegeneration. In Alzheimer's disease, reduced cerebral blood flow and impaired angiogenesis contribute to pathology; dysregulated FLT1 signaling disrupts the balance between pro-angiogenic VEGFR-2 signaling and anti-angiogenic FLT1 signaling, compromising neuronal glucose and oxygen delivery. Altered FLT1 expression has been observed in post-mortem Alzheimer's brain tissue, correlating with cognitive decline severity.
In Parkinson's disease, neuroinflammation mediated by aberrant VEGF/FLT1 signaling in microglia and infiltrating immune cells perpetuates dopaminergic neuronal death. FLT1 signaling in myeloid cells regulates their pro-inflammatory cytokine production and infiltration into the brain parenchyma, exacerbating neurodegeneration.
The VEGF/FLT1 axis also modulates blood-brain barrier integrity through effects on vascular endothelial cadherin and tight junction protein expression. Excessive soluble FLT1 production disrupts this barrier function, promoting neuroinflammation and neuronal death across multiple neurodegenerative conditions.
Molecular Mechanisms
FLT1 signal transduction in neuronal survival operates through PI3K/Akt-mediated phosphorylation of pro-apoptotic proteins (BAD, FoxO) and activation of glycogen synthase kinase-3 beta (GSK-3β) inhibition. In endothelial cells, FLT1 promotes survival via the Src/FAK pathway and regulates permeability through VE-cadherin modulation. The balance between VEGFR-1 and VEGFR-2 signaling determines whether tissues undergo inflammatory quiescence or pathological angiogenesis; excessive FLT1 activation promotes immune tolerance and anti-angiogenic responses, while its deficiency enhances VEGFR-2-driven pro-angiogenic signaling.
Clinical/Research Significance
Therapeutic targeting of FLT1 is being explored in neurodegenerative diseases. Modulating the VEGF/FLT1 axis represents a potential intervention point, with soluble FLT1-based therapeutics and FLT1 antagonists under investigation. Understanding FLT1's role in blood-brain barrier maintenance and neuroinflammation may yield novel biomarkers for disease progression and prognosis.